Skip to main content

Table 1 Univariate and multivariate logistic regression model for pCR according to clinicopathological and treatment factors

From: In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment

Factors

   

pCR

  

Univariate analysis

Multivariate analysis

OR

95% CI

p value

OR

95% CI

p value

Age < 50y vs. ≧50y

1.307

0.798–2.141

0.287

   

cT1-2 vs. cT3

 

0.759

0.368–1.566

0.456

   

cN0 vs. cN1-3

 

0.726

0.410–1.285

0.272

   

Grade I-II vs. III

 

1.418

0.871–2.310

0.160

   

HR positive vs. negative

3.767

2.256–6.290

< 0.001

1.907

1.014–3.584

0.045

HER2 RNAscope score 1–4 vs. 5

10.545

5.893–18.872

< 0.001

10.865

5.547–21.281

< 0.001

TIL < 20% vs. ≧20%

2.082

1.226–3.534

0.007

2.057

1.068–3.961

0.031

NCTT subgroup

      
 

EC(F) to TH(P) vs. TH(P)

2.307

1.049–5.072

0.038

2.680

0.941–7.634

0.065

 

EC(F) to TH(P) vs. TH(P) to EC(F)

1.004

0.518–1.948

0.990

1.363

0.599–3.099

0.460

 

EC(F) to TH(P) vs. TCarboH(P)

1.405

0.700-2.819

0.339

1.096

0.435–2.764

0.846

Anti-HER2 blockade (mono vs. dual)

1.444

0.885–2.359

0.142

2.178

1.141–4.159

0.018

  1. Bold font indicates statistical significance at the p < 0.05 level